Abstract
The new guidelines for the management of dyslipidemia published in September 2019 brought a new paradigm for cardiovascular prevention, which can be summarized in the principle "the sooner the lower, the better". We have known for a long time that manifestation of a major atherosclerotic vascular complication, underlies exposition of the vascular wall to a so-called cumulative burden of LDL-C (LDL-C) of 150 mmol/L.
This could be determined as the average annual concentration of LDL-C multiplied by the number of years it acts. The current approach may be too conservative for some patients and it can be stated that practically every patient with other risk factors deserves a "lipid" intervention.
The most common of these is undoubtedly arterial hypertension. However, the gap between the diagnosis of arterial hypertension and dyslipidemia remains nearly 10 years.
Patient adherence is also important for the success of preventive intervention, which can be influenced by the selection of proven drugs with a good safety profile. One of the proven and simple ways to improve adherence is the choice of fixed combinations.
A fixed combination of atorvastatin with perindopril (Euvascor(R)), the two most common active substances in the treatment of dyslipidemia and hypertension, has recently entered clinical practice. It will certainly be widely used as initial treatment as well as in more complex combination regimens.